Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 381-390

  Calverley, Peter M ^a   Postma, Dirkje S ^b   Anzueto, Antonio R ^c,d   Make, Barry J ^e   Eriksson, Göran ^f   Peterson, Stefan ^g   Jenkins, Christine R ^h  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY OF TEXAS   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f University Hospital   (United States)

^g StatMind AB   (Sweden)

^h UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Anti inflammatories; Bronchodilator effect; Chronic obstructive pulmonary disease; Predictors; Risk assessment; Risk factors

Indexed keywords

BRONCHODILATING AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FORMOTEROL; BUDESONIDE; FORMOTEROL FUMARATE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FORCED EXPIRATORY VOLUME; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POST HOC ANALYSIS; PREVALENCE; RISK REDUCTION; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREATMENT DURATION; TREATMENT RESPONSE; AGED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; FORMOTEROL FUMARATE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SYMPTOM FLARE UP; TIME FACTORS;

EID: 84959365536     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S93303     Document Type: Article

References (30)

1. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775-789.
2. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22(6):912-919.
3. Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008; 68(14):1975-2000.
4. Aliverti A, Rodger K, Dellaca RL, et al. Effect of salbutamol on lung function and chest wall volumes at rest and during exercise in COPD. Thorax. 2005;60(11):916-924.
5. O’Donnell D, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 160(2):542-549.
6. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease [online]. 2011; Available from: http://www.goldcopd.org/. Accessed September 25, 2012.
7. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155(4): 1283-1289.
8. Niewoehner DE, Collins D, Erbland ML. Relation of FEV(1) to clinical outcomes during exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. Am J Respir Crit Care Med. 2000;161(41):1201-1205.
9. Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease. Thorax. 2005;60(4):301-304.
10. Jones P, Donohue J, Nedelman J, Pascoe S, Pinault G, Lassen C. Correlating changes in lung function with patient outcomes in chronic obstructive pulmonary disease: a pooled analysis. Respir Res. 2011; 12:161.
11. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009; 69(5):549-565.
12. Sharafkhaneh A, Southard JG, Goldman M, Uryniak T, Martin UJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012;106(2):257-268.
13. Standardization of spirometry, 1994 update. American Thoracic Society. Am J Respir Crit Care Med. 1995;152(3):1107-1136.
14. Cazzola M, MacNee W, Martinez FJ, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J. 2008; 31(2):416-469.
15. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111-124.
16. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19(3): 398-404.
17. Calverley PM, Spencer S, Willits L, Burge PS, Jones PW, Group IOSLDE. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest. 2003;124(4):1350-1356.
18. Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med. 2013;1(7):564-573.
19. Jones PW. St George’s respiratory questionnaire: MCID. COPD. 2005; 2(1):75-79.
20. Jenkins CR, Jones PW, Calverley PM, et al. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res. 2009;10:59.
21. Decramer M, Celli B, Kesten S, Lystig T, Mehra S, Tashkin DP. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374(9696):1171-1178.
22. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. New Engl J Med. 2010;363(12): 1128-1138.
23. Make BJ, Eriksson G, Calverley PM, et al. A score to predict short-term risk of COPD exacerbations (SCOPEX). Int J COPD. 2015;10: 201-209.
24. Wan ES, DeMeo DL, Hersh CP, et al. Clinical predictors of frequent exacerbations in subjects with severe chronic obstructive pulmonary disease (COPD). Respir Med. 2011;105(4):588-594.
25. Al-ani S, Spigt M, Hofset P, Melbye H. Predictors of exacerbations of asthma and COPD during one year in primary care. Family Pract. 2013; 30(6):621-628.
26. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax. 2012;67(8):701-708.
27. Stevenson NJ, Walker PP, Costello RW, Calverley PM. Lung mechanics and dyspnea during exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(12):1510-1516.
28. Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004;23(5):698-702.
29. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435-442.
30. Kesten S, Plautz M, Piquette CA, Habib MP, Niewoehner DE. Premature discontinuation of patients: a potential bias in COPD clinical trials. Eur Respir J. 2007;30(5):898-906.